Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors

被引：0
|
作者：
Meng, Yanchun
Zhang, Jian
Zhao, Chuanhua
Cheng, Ying
Zhu, Liming
Song, Zhengbo
Xu, Nong
Wang, Zhen
Wang, Yanping
Du, Yiqun
Jing, Deqiang
Chen, Dinglu
Qu, Qiaofeng
Zhao, Xiwen
Li, Wei
Lu, Qiying
Tian, Wenzhi
Xu, Jianming
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Phase Clin Trial Ctr 1, Shanghai, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[3] Sch Med, Beijing, Peoples R China
[4] Jilin Canc Hosp, Changchun, Peoples R China
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China
[6] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[7] Linyi Canc Hosp, Linyi, Shandong, Peoples R China
[8] ImmuneOnco Biopharmaceut Shanghai Inc, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15185
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Keedy, Vicki L.
    Lenz, Heinz-Josef
    Saltz, Leonard
    Whisenant, Jennifer G.
    Berlin, Jordan D.
    Camacho, Luis H.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 860 - 868
  • [2] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Vicki L. Keedy
    Heinz-Josef Lenz
    Leonard Saltz
    Jennifer G. Whisenant
    Jordan D. Berlin
    Luis H. Camacho
    Investigational New Drugs, 2018, 36 : 860 - 868
  • [3] A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors
    Ma, Fei
    Xu, Nong
    Tang, Huoling
    Zhou, Yuhong
    Wei, Ziping
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] FS-1502, an anti-HER2 ADC, in Patients with HER2-Expressing Advanced Solid Tumors: A Phase 1a Dose-Escalation Study
    Li, Qiao
    Wang, Xian
    Cheng, Ying
    Liu, Yunjiang
    Chang, Jianhua
    Wang, Zhuo
    Wu, Chunjiao
    Wang, Mingxia
    Hui, Ai-Min
    Wu, Zhuli
    Jin, Yongli
    Huang, Xin
    Zhong, Liping
    Diao, Lei
    Zhao, Han
    Xu, Binghe
    CANCER RESEARCH, 2023, 83 (05)
  • [5] Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
    Hu, Xichun
    Zhang, Jian
    Liu, Rujiao
    Gao, Shuiping
    Qing, Yan
    Yi, Shuli
    Yuan, Juanjuan
    Chen, Hong
    Fan, Bin
    Zheng, Haochuan
    Wang, Jingyi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors
    Li, Bob T.
    Pegram, Mark D.
    Lee, Keun-Wook
    Sharma, Manish
    Lee, Jeeyun
    Spira, Alexander I.
    Hanna, Glenn J.
    Kang, Yoon-Koo
    Rasco, Drew W.
    Moore, Kathleen N.
    Weinberg, Benjamin Adam
    Alonso, Michael N.
    Ptacek, Jason
    Yin, Ming
    Tapia, Coya
    Xu, Lu
    Perez, Edith A.
    Dumbrava, Ecaterina Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Moore, Kathleen N.
    Chua, Cynthia C.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Harrow, Kim
    Liang, Chris
    ONCOLOGIST, 2019, 24 (04): : 455 - E121
  • [8] A multicenter, phase 1b, first-in-human dose-escalation study of ADXS31-164, a Listeria monocytogenes-LLO immunotherapy, in patients with HER2-expressing solid tumors
    Tan, A. R.
    Olszanski, A.
    Golan, T.
    Mauro, D.
    Rugo, H.
    CANCER RESEARCH, 2016, 76
  • [9] A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors
    Hurvitz, Sara A.
    Hamilton, Erika P.
    Spira, Alexander I.
    Pohlmann, Paula R.
    Giordano, Antonio
    Clifton, Katherine
    Anderson, Barry Douglas
    Dutta, Sujoy
    Mangipudi, Umesh
    Saini, Shikha
    Palacino, James
    Karunaratne, Tina
    Greensmith, Dennise
    Christensen, Olaf
    Wilks, Sharon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors
    Dumbrava, E. E.
    Calvo, E.
    Garralda, E.
    Ryu, M. H.
    Oh, D. Y.
    Bai, L. Y.
    Chung, W.
    Rojas Laimito, K. I.
    Yildirim, O.
    Masciari, S.
    Kang, K.
    Buday, B.
    Rharbaoui, F.
    Abbadessa, G.
    Moreno Garcia, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S647 - S647
12345